Are you eagerly awaiting news of FDA approval for low dose atropine for myopia management? Several pharmaceutical companies are pursuing FDA approval and are finalizing Phase III clinical studies for review. Currently low dose atropine for myopia management is prescribed as an off-label use by doctors to slow the progression of myopia, backed by numerous international studies including the ATOM 1 and 2...